Expression of hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts Antileukemic effects

Clinical Cancer Research

Volumn 21, Issue 10, 2015, Pages 2388-2398

  Wellbrock, Jasmin ^a   Latuske, Emily ^a   Kohler, Julian ^a   Wagner, Katharina ^b   Stamm, Hauke ^a   Vettorazzi, Eik ^a   Vohwinkel, Gabi ^a   Klokow, Marianne ^a   Uibeleisen, Roswitha ^b   Ehm, Patrick ^a   Riecken, Kristoffer ^a   Loges, Sonja ^a   Thol, Felicitas ^b   Schubert, Claudia ^a   Amling, Michael ^a   Jucker, Manfred ^a   Bokemeyer, Carsten ^a   Heuser, Michael ^b   Krauter, Jurgen ^b   Fiedler, Walter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; PROTEIN INHIBITOR; PROTEIN PATCHED 1; SHORT HAIRPIN RNA; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR GLI3; TUMOR MARKER; G PROTEIN COUPLED RECEPTOR; GANT 61; GLI1 PROTEIN, HUMAN; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SMO PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANTILEUKEMIC EFFECT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COLONY FORMATION; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MALE; MEDIATOR; MULTICENTER STUDY (TOPIC); MUTATIONAL ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; ANIMAL; CANCER TRANSPLANTATION; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MORTALITY; NONOBESE DIABETIC MOUSE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCID MOUSE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HEDGEHOG PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRIDINES; PYRIMIDINES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84934963798     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1059     Document Type: Article

References (48)

1. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8.
2. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev ClinOncol 2011; 8:97-106.
3. Doan PL, Chute JP. The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia 2012;26:54-62.
4. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001;411:349-54.
5. Schlenk RF, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, et al. All-Trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia-results of the AMLSG 07-04 randomized treatment trial. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego (CA). Abstract nr 80.
6. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, et al. Prediction of molecular subtypes in acutemyeloid leukemia based on gene expression profiling. Haematologica 2009;94:131-4.
7. Lowenberg B, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Vellenga E, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997;15:3496-506.
8. Fiedler W, Henke RP, Ergun S, Schumacher U, Gehling UM, Vohwinkel G, et al. Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome: A case report. Cancer 2000;88:344-51.
9. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004;104:2752-60.
10. Lam CW, Xie J, To KF, Ng HK, Lee KC, Yuen NW, et al. A frequent activated smoothened mutation in sporadic basal cell carcinomas. Oncogene 1999;18:833-6.
11. Hothorn T, Hornik K, Zeileis A. Unbiased recursive partitioning: A conditional inference framework. J Comput Graphical Stat 2006;15:651-74.
12. Friendly M. A fourfold display for 2 by 2 by k tables. York University, Psychology Department, York, Ontario, Canada; 1994.
13. Eberl M, Klingler S, Mangelberger D, Loipetzberger A, Damhofer H, Zoidl K, et al. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol Med 2012;4:218-33.
14. Dierks C, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008;14:238-49.
15. Hegde GV, Peterson KJ, Emanuel K, Mittal AK, Joshi AD, Dickinson JD, et al. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: A potential new therapeutic target. Mol Cancer Res 2008;6:1928-36.
16. Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996;14:78-81.
17. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391:90-2.
18. ten Haaf A, Bektas N, von Serenyi S, Losen I, Arweiler EC, Hartmann A, et al. Expression of the glioma-Associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. BMC Cancer 2009;9:298.
19. Tojo M, Kiyosawa H, Iwatsuki K, Nakamura K, Kaneko F. Expression of the GLI2 oncogene and its isoforms in human basal cell carcinoma. Br J Dermatol 2003;148:892-7.
20. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res 2007;67:2187-96.
21. Yan M, Wang L, Zuo H, Zhang Z, Chen W, MaoL, et al. HH/GLI signalling as a new therapeutic target for patients with oral squamous cell carcinoma. Oral Oncol 2011;47:504-9.
22. Zhang D, Cao L, Li Y, Lu H, Yang X, Xue P. Expression of glioma-Associated oncogene 2 (Gli 2) is correlated with poor prognosis in patients with hepatocellular carcinoma undergoing hepatectomy. World J Surg Oncol 2013;11:25.
23. Park KS, Martelotto LG, Peifer M, SosML, Karnezis AN, Mahjoub MR, et al. A crucial requirement forHedgehog signaling in small cell lung cancer. Nat Med 2011;17:1504-8.
24. Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chai L, Wichterle H, et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. ProcNatl Acad SciUS A 2003;100:4616-21.
25. Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, et al. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res 2011;17:4682-92.
26. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010;2:51ra70.
27. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLImediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A 2007;104:8455-60.
28. Wang Y, Han C, Lu L, Magliato S, Wu T. Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. Hepatology 2013;58:995-1010.
29. Wickstrom M, Dyberg C, Shimokawa T, Milosevic J, Baryawno N, Fuskevag OM, et al. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer 2013;132:1516-24.
30. Desch P, Asslaber D, Kern D, Schnidar H, Mangelberger D, Alinger B, et al. Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells. Oncogene 2010;29:4885-95.
31. Huang L, Walter V, Hayes DN, Onaitis M. Hedgehog-GLI signaling inhibition suppresses tumor growth in squamous lung cancer. Clin Cancer Res 2014;20:1566-75.
32. Mazumdar T, DeVecchio J, Shi T, Jones J, Agyeman A, Houghton JA. Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res 2010;71:1092-102.
33. Pan D, Li Y, Li Z, Wang Y, Wang P, Liang Y. Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycin. Leuk Res 2012;36:742-8.
34. Tostar U, Toftgard R, Zaphiropoulos PG, Shimokawa T. Reduction of human embryonal rhabdomyosarcoma tumor growth by inhibition of the hedgehog signaling pathway. Genes Cancer 2010;1:941-51.
35. Agyeman A, Jha BK, Mazumdar T, Houghton JA. Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. Oncotarget 2014;5:4492-503.
36. Bagger FO, Rapin N, Theilgaard-Monch K, Kaczkowski B, Jendholm J, WintherO, et al. HemaExplorer: A Web server for easy and fast visualization of gene expression in normal and malignant hematopoiesis. Blood 2012;119:6394-5.
37. Shih AY, Schairer A, Barrett CL, Geron I, Court Recart AC, Goff D, et al. Cycling toward leukemia stem cell elimination wtih a selective sonic hedgehog antagonist. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego (CA). Abstract nr 3776.
38. Kobune M, Takimoto R, Murase K, Iyama S, Sato T, Kikuchi S, et al. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci 2009;100:948-55.
39. Liu Z, Xu J, He J, Zheng Y, Li H, Lu Y, et al. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood 2014;124:2061-71.
40. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:2502-11.
41. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72.
42. Italiano A, Le Cesne A, Cassier PA, Ray-Coquard I, Domont J, Piperno-Neumann S, et al. GDC-0449 in patients with advanced chondrosarcomas: A French Sarcoma Group (FSG)/French and U.S. National Cancer Institutes phase II collaborative study. J Clin Oncol 30, 2012 (suppl; abstr 10005).
43. Ko AH, LoConte NK, Kantoff E, Ross RW, Trehu EG, Tempero MA, et al. A phase Ib trial of FOLFIRINOX plus saridegib, an oral hedgehog (Hh) inhibitor, in pts with advanced pancreatic cancer (PDAC). J Clin Oncol 30, 2012 (suppl; abstr 3105).
44. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361:1173-8.
45. Jamieson C, Cortes JE, Oehler V, Baccarani M, Kantarjian HM, Papayannidis C, et al. Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies. In: Proceedings of the 53rd ASHAnnual Meeting and Exposition; 2011 Dec 10-13; San Diego (CA). Abstract nr 424.
46. Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA, Mauviel A. TGF-beta/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res 2011;71:5606-10.
47. LauthM, Toftgard R. Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. Cell Cycle 2007;6:2458-63.
48. Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med 2014;20:732-40.